Cowen and Company Health Care Conference Pfizer Oncology Andy Schmeltz Global President, Pfizer Oncology March 14, 2018
Forward Looking Statements This presentation includes forward-looking statements about, among other things, Pfizer’s oncology in-line products and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Pfizer's oncology products and product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors that May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements. 2
Pfizer Oncology Growth Trajectory Growing in-line portfolio fueled by IBRANCE & XTANDI with potential for multiple launches on the horizon Mindset Opportunistic & Niche Growth & Leadership Revenue $B DACOMITINIB LORLATINIB GLASDEGIB TALAZOPARIB E* 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 E* 2020 E* # Approved 2 3 5 5 5 6 7 10 12 14 14 Medicines* # Approved 3 5 7 8 8 9 11 17 20 21 28 Indications* Curve is for illustrative purposes only *numbers for 2018-2020 reflect potential approvals and indications that are expected and may not materialize 3
A Rich Oncology Pipeline as of February, 2018 Cell Cycle & Angiogenesis Immunotherapy Metabolism Cell Signal Antibody Drug Therapeutic Transduction / Conjugate Vaccine Oncogenic Driver Anti-MCSF (PD-360324)(A626) avelumab* bosutinib* Anti-PD1 OX-40 NSCLC, Ovarian, RCC, (PF-06801591)(B801) (PF-04518600)(B060) CML 1L (EU) Gastric, urothelial,SCCHN avelumab* axitinib* dacomitinib* BCMA CD3 p-cadherin LP DART NSCLC, SCLC, H&N, (PF-06863135)(C107) RCC Adj NSCLC (US,EU) (PF-06671008)(B783) Melanoma, TNBC, MCC crizotinib* enzalutamide* enzalutamide* EGFR T790M PTK7 ALCL / Neuroblastoma (PF-06747775)(B797) CRPC, HSPC CRPC (US,EU) (PF-06647020)(B766 ) (pediatric CRCs) gemtuzumab glasdegib* GD3 lorlatinib UCART19 ozogamicin (PF-06688992)(B802) AML (Fit & Unfit) ALK+ NSCLC 1L (PF-06883541)(C119) AML (EU) lorlatinib gedatolisib sunitinib palbociclib* utomilumab ALK+ NSCLC 2L+ ( PF-05212384)(B215) Pediatric GIST BC ( PF-05082566)(B164) (US,EU,JPN) talazoparib* talazoparib* NG-HER2 VBIR1 sunitinib (PF-06804103)(C054 ) CRPC gBRCA mut mBC, CRPC (PF-06753512)(B779) RCC Adj (EU) 13 4 6 6 Registration 1 Phase 1 Phase 2 Phase 3 1 Registration/Approvals: Only includes major regions (US, EU, JPN, CHN). * Additional clinical studies being conducted in other tumor types/segments and earlier phases. 4
Focused to Realize Our Vision To Be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer Key Focus Areas IBRANCE & Pipeline XTANDI* • Partner with key • Talazoparib: PARP • Innovative and stakeholders in the inhibitior meaningful patient breast and prostate engagement • Avelumab: backbone cancer communities PD-L1 therapy • Advancing access • Generate evidence via outcomes and • Identify and for broader and real world evidence interrogate rational optimal use combinations with IO • Redefining life with and non-IO cancer mechanisms *Pfizer and Astellas jointly commercialize XTANDI in the United States 5
Q&A Andy Schmeltz Global President, Pfizer Oncology
Recommend
More recommend
